SAR442168
Phase 3- Indications
- Multiple sclerosis
Company intelligence / Profile preview
Principia Biopharma
South San Francisco, California, United Statessanofi.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Phase 3
01
Overview
Principia developed a pipeline of oral small molecule therapies for immune-mediated diseases, oncology, and CNS conditions. Its lead asset rilzabrutinib was in Phase 3 for pemphigus; PRN2246/SAR442168, a BTK inhibitor crossing the blood-brain barrier, entered multiple Phase 3 trials in MS with Sanofi; PRN473 Topical was in early clinical development. The company’s platform enabled best-in-class candidates with improved safety/selectivity profiles. Clinical results included strong efficacy signals such as an 85% reduction in MRI lesions for MS patients treated with SAR442168 compared to placebo[9].
- Therapeutic areas
- OncologyImmunologyHematologyDermatologyNeurology
- Modalities
- Small molecules (reversible and irreversible covalent inhibitors)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Sanofi S.A.: Exclusive worldwide license/collaboration on BTK inhibitors including SAR442168/MS program since November 2017; full acquisition completed September–October 2020.[7]Genzyme Corporation/Sanofi Genzyme division collaboration on CNS indications.[4]
Beyond the preview
Go deeper on Principia Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Principia Biopharma.